1. Home
  2. TENX vs FRMM Comparison

TENX vs FRMM Comparison

Compare TENX & FRMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$2.13

Market Cap

71.1M

Sector

Health Care

ML Signal

N/A

FRMM

Forum Markets Incorporated Common Stock

N/A

Current Price

$5.86

Market Cap

75.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
FRMM
Founded
1967
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.1M
75.7M
IPO Year
2001
2017

Fundamental Metrics

Financial Performance
Metric
TENX
FRMM
Price
$2.13
$5.86
Analyst Decision
Strong Buy
Buy
Analyst Count
3
1
Target Price
$29.67
$5.00
AVG Volume (30 Days)
9.0M
170.2K
Earning Date
05-15-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,547,000.00
Revenue This Year
N/A
$183.55
Revenue Next Year
N/A
$166.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$1.76
52 Week High
$19.40
$7.15

Technical Indicators

Market Signals
Indicator
TENX
FRMM
Relative Strength Index (RSI) 23.92 49.06
Support Level $1.31 $5.38
Resistance Level $14.15 $5.84
Average True Range (ATR) 0.20 0.42
MACD 0.17 -0.04
Stochastic Oscillator 75.00 44.14

Price Performance

Historical Comparison
TENX
FRMM

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About FRMM Forum Markets Incorporated Common Stock

Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.

Share on Social Networks: